Bicara Therapeutics (BCAX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Bicara Therapeutics (BCAX) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +1.00 of bullish evidence against -0.26 bearish.

Bicara Therapeutics last closed at $16.56, -4.22% on the session.

Against the IVW growth benchmark the position is -4.83% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

17 graded predictions for BCAX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Bicara Therapeutics in the 20th percentile on return on equity, where 100 is best.

Bicara Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.14B.

StockMap tracks Bicara Therapeutics as the 125th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Bicara Therapeutics ranks 200th of 365 in the group, against a group median of -0.21.